Key facts
- D3 Bio reported a 78.0% ORR and 12.4 months median PFS for elisrasib monotherapy in first-line NSCLC.
- The combination of elisrasib and pembrolizumab achieved an 81.3% ORR.
- Novartis' experimental drug showed over 52% of patients previously treated with Pluvicto had their PSA levels fall by half.
- The European Commission approved Amgen's Imdyetra for extensive-stage small cell lung cancer.
- Imdyetra showed a 40% reduction in the risk of death compared to chemotherapy.
- Ansun Biopharma's Phase 3 trial for DAS181 will expand its sample size.
- IDEAYA Biosciences and Roche will collaborate on a pancreatic cancer drug trial.
- Biond Biologics and GIBF closed an $8 million investment and collaboration.
- WuXi Biologics' Singapore CRDMO Hub topped out its Drug Product facility.
- Mezzion Pharma's FUEL-2 Phase 3 study enrollment is on track for completion in 2026.
- Aphranel achieved EU MDR certification and delivered over 150,000 syringes.
- Astrana Health was named to the 2026 Fortune 1000 List.
Multiple companies are reporting progress in oncology drug development and clinical trials. D3 Bio presented preliminary data for elisrasib, a KRAS G12C inhibitor, in first-line non-small cell lung cancer (NSCLC). In monotherapy, elisrasib achieved a 78.0% objective response rate (ORR) and a 12.4-month median progression-free survival (PFS). When combined with pembrolizumab, the ORR increased to 81.3%, with manageable safety profiles reported.
Novartis' experimental actinium-based drug has shown anti-tumour activity in an early study involving prostate cancer patients. Over 52% of patients who had previously received Pluvicto experienced a reduction in PSA levels by half. Higher response rates were observed in treatment-naive patients. Analysts suggest that managing potential side effects will be a critical factor as Novartis moves forward with larger clinical trials.
The European Commission has granted approval for Amgen's Imdyetra for patients with extensive-stage small cell lung cancer. This approval is based on Phase 3 trial results that indicated a 40% reduction in the risk of death when compared to standard chemotherapy, providing a new therapeutic option.
Ansun Biopharma's Phase 3 development of DAS181 for immunocompromised patients suffering from parainfluenza infection will continue. This decision follows a recommendation from the study's independent Data Monitoring Committee, which advised expanding the sample size after an interim analysis suggested the study is performing well. Mezzion Pharma has completed a regulatory milestone for its FUEL-2 Phase 3 study, with an independent review confirming the study will proceed as planned, and enrollment is on track for completion in 2026.
In other collaborations, IDEAYA Biosciences and Roche will partner on a clinical trial to evaluate IDE892 in combination with RG6505 for pancreatic cancer. This agreement includes upfront and potential milestone payments to IDEAYA. Biond Biologics and Guangzhou-Israel Biotechnology Fund (GIBF) have finalized an $8 million investment and collaboration to advance oncology programs in China.
WuXi Biologics announced the topping out of its Drug Product facility at its Singapore CRDMO Hub, signifying progress in developing integrated drug development and manufacturing services. Satsuma Pharmaceuticals is set to present data from its migraine treatment development program at the American Headache Society's 68th Annual Scientific Meeting. Aphranel celebrated its first anniversary on May 20, 2026, having achieved EU MDR certification and launched its Arc product line, delivering over 150,000 syringes since its launch on May 8, 2025.
Astrana Health, Inc. has been named to the 2026 Fortune 1000 List, acknowledging its significant revenue growth. Vaniam Group and Women Leaders in Oncology, through Conquer Cancer, the ASCO Foundation, funded the 2026 Young Investigator Awards for physician-scientists Nia Beckley and Jordyn Silverstein. Bio Ascend, a Vaniam Group company, has taken over stewardship of the iwNHL and iwMyeloma workshops.